Enhertu Improves Survival for Metastatic “HER2-Low” Breast Cancer | Cancer Currents Blog

New clinical trial results could open the door to more effective treatments for about half of all people with metastatic breast cancer—those whose tumors don’t have high levels of the protein HER2—who until now have had limited treatment options.

In the trial, people with metastatic breast cancer who were treated with the HER2-targeted drug trastuzumab deruxtecan (Enhertu) lived nearly twice as long without their cancer growing, and lived 6 months longer overall, than those treated with standard chemotherapy. All patients in the study had tumors classified as “HER2-low” and had previously been treated for metastatic breast cancer with at least one other drug.

Read the blog at cancer.gov